click on circles to display study description...
Nuvaxovid (NVX-CoV2373) Novavax (n=-9) vs. placebo (n=-9)
randomized controlled trial
NVX-CoV2373
placebo
COVID-19 prophylaxis (excluding children)
observer-blinded
119 locations in the United States and Mexico
Efficacy endpoints were accrued from January 25 through April 30, 2021, a time when the Alpha (B.1.1.7) variant became the predominant strain in the U.S
Nuvaxovid (NVX-CoV2373) Novavax (n=2199) vs. placebo (n=2188)
randomized controlled trial
NVX-CoV2373 2 doses
two doses, administered 21 days apart, of NVX-CoV2373 nanoparticle vaccine(5 μg recombinant spike protein with 50 μg Matrix-M1 adjuvant)
placebo
COVID-19 prophylaxis (excluding children)
B.1.351 (501Y.V2) variant was largely predominant during trial efficacy endpoint accrual
double-blind
South Africa
phase 2a/b
powered by vis.js Network
-
About us
-
Contact us
-
Method
-
RSS
Made with
in Lyon
-
Credits
-
Privacy policy
-
An extraction panel is open